TRK-700 + digoxin

TRK-700 + digoxin is a **combination drug** comprised of **TRK-700** and **digoxin**. TRK-700 is an investigational small molecule inhibitor targeting **cyclooxygenase-1 (COX-1)**, developed by Toray Industries, investigated primarily for neuropathic pain conditions including postherpetic neuralgia and fibromyalgia[2]. Digoxin is a well-established cardiac glycoside that inhibits the **sodium-potassium ATPase**, increasing intracellular calcium in cardiac myocytes and thus enhancing cardiac contractility[1]. TRK-700 + digoxin would combine analgesic and cardiotonic mechanisms, though no published clinical results or combination products of TRK-700 with digoxin exist as of current data and no safety or efficacy data for this specific combination are available.